Multicenter study of high-dose daptomycin for treatment of enterococcal infections
about
Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsVancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal managementDaptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococciDefining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.Characterization of aminoglycoside resistance and virulence genes among Enterococcus spp. isolated from a hospital in China.β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.Real-World Treatment of Enterococcal Infections with Daptomycin: Insights from a Large European Registry (EU-CORE)Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience.Antimicrobial Stewardship Intervention and Feedback to Infectious Disease Specialists: A Case Study in High-Dose Daptomycin.Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.The prevention and management of infections due to multidrug resistant organisms in haematology patientsVancomycin-resistant enterococcal bacteremia pharmacotherapy.Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British HeTherapeutic options for vancomycin-resistant enterococcal bacteremia.Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain.Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence.Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-resistant Enterococcus faecium Isolates in an In Vitro PK/PD Model of Infection.Treatment of Vancomycin-Resistant Enterococci: Focus on Daptomycin.Daptomycin nonsusceptible vancomycin resistant Enterococcus bloodstream infections in patients with hematological malignancies: risk factors and outcomes.Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia.What's New in the Treatment of Enterococcal Endocarditis?Daptomycin experience in patients with human immunodeficiency virus and resistant gram-positive infections.Daptomycin is safe and effective for the treatment of gram-positive cocci infections in solid organ transplantation.Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
P2860
Q26752922-5475B2CD-F6EB-4CFD-B132-C11B50141D5DQ26798630-0B7CE050-D743-48BE-9A04-0F45009DDA17Q26851754-791A6E15-CD46-4109-84E1-7D5D579BF4A4Q34057475-F8F64F5F-A959-40C0-B5CB-7A0C81676EE0Q35228092-02ACDF4E-AA92-423B-95CD-772FD6F0D379Q35385108-FAD2B011-E389-4E05-8327-777425501DC0Q35802607-6F15D36C-579F-48A2-8812-BEB35D2BF211Q35848781-2DD88571-E7A8-48A3-9C26-D4FF48CACED1Q35974360-68FB9566-121F-4E79-AE73-36D86F29CBEAQ36073400-64898D43-1E9B-4F0D-8691-09707DF9B4F6Q36373724-770C74FF-E417-4D5C-BF2D-603FB501F73DQ36683458-408CF9C9-8D41-4C7F-8D7D-6F63403673E6Q36686882-089F483F-324A-4025-AFF5-A6F11E8A623AQ37287661-A8004286-F199-4D42-8F1C-B5BE944CC4BDQ38171538-65B429E6-5310-407D-AE45-9221895B7F56Q38263421-63016BE7-00CA-43E4-B00C-17BA5DEA422CQ38263821-A62C9F31-DE99-44E0-B25D-EF57B1CD3196Q38347869-420073AE-5349-43C2-B091-84B4B9119C8CQ38620812-2FF5F943-5B84-45E2-A5F5-B2B77D96B1A9Q38990504-8BBFDCDF-06E2-4254-A6BE-DFB0FFC2CC44Q39168565-951F44DB-0047-4D63-9869-A8A0D53E0372Q40103272-A6FBBBFD-CC16-43CD-8005-CCEC82763752Q40105754-767555F4-CE46-4780-A615-7DDC13C63197Q40254524-A7D51D40-8E23-45DA-84ED-C65B7280C922Q40280282-D028BF18-F142-49B6-A098-89D21C7AF6D9Q41368979-B18FB940-5793-4D43-9DD9-BFB85DEC88EBQ41699405-37783101-37A9-4859-B369-79A8161D6980Q42215009-ED989E78-F962-45D0-8CA9-4071262AC7A1Q48357083-3E459178-AB40-4A7C-B54D-BC4E38BE7CAE
P2860
Multicenter study of high-dose daptomycin for treatment of enterococcal infections
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Multicenter study of high-dose daptomycin for treatment of enterococcal infections
@en
Multicenter study of high-dose daptomycin for treatment of enterococcal infections.
@nl
type
label
Multicenter study of high-dose daptomycin for treatment of enterococcal infections
@en
Multicenter study of high-dose daptomycin for treatment of enterococcal infections.
@nl
prefLabel
Multicenter study of high-dose daptomycin for treatment of enterococcal infections
@en
Multicenter study of high-dose daptomycin for treatment of enterococcal infections.
@nl
P2093
P2860
P356
P1476
Multicenter study of high-dose daptomycin for treatment of enterococcal infections
@en
P2093
Anthony M Casapao
Brian A Potoski
Christopher W Crank
Debra A Goff
Donald P Levine
George Sakoulas
Jing J Zhao
John Segreti
Michael J Rybak
Ravina Kullar
P2860
P304
P356
10.1128/AAC.00526-13
P407
P577
2013-06-17T00:00:00Z